Company: IXHL
Filing Date: 2025-03-24
Form Type: S-3
Source: 0001013762-25-001587
Chunk: 15

Company: Incannex Healthcare Inc.
Filing Date: 2025-03-24
Form: S-3
Chunk 15
---
 candidates and the consequences resulting from the delay in obtaining necessary regulatory approvals; |

| · | the timing, scope or likelihood of regulatory filings and                                                         
 approvals and our ability to obtain and maintain regulatory approvals for our drug candidates for any indication; |

| · | the pricing, coverage and reimbursement of our drug candidates, 
 if approved and commercialized;                                 |

| · | the rate and degree of market acceptance and clinical utility 
 of our drug candidates;                                       |

| · | our expectations around feedback from and discussions with                                          
 regulators, regulatory development paths and with respect to Controlled Substances Act designation; |

| · | our ability to maintain effective patent rights and other                                                                             
 intellectual property protection for our drug candidates, and to prevent competitors from using technologies we consider important to 
 the successful development and commercialization of our drug candidates;                                                              |

| · | our ability to comply with applicable listing standards within                                               
 the compliance period and to maintain the listing of shares of our Common Stock on the Nasdaq Global Market; |

| · | our estimates regarding expenses, revenues, financial performance                                         
 and capital requirements, including the length of time our capital resources will sustain our operations; |

| · | our ability to commercialize drug candidates and to generate 
 revenues;                                                    |

| · | our financial condition, including our ability to obtain the                                                        
 funding necessary to advance the development of our drug candidates and our ability to continue as a going concern; |

<div align='center'>7</div>

| · | our ability to comply with the provisions and requirements                                       
 of our debt arrangements and to pay amounts owed, including any amounts that may be accelerated; |

| · | our ability to retain and attract qualified employees, directors, 
 consultants and advisors;                                         |

| · | our ability to continue to comply with applicable privacy         
 laws and protect confidential information from security breaches; |

| · | how recent and potential future changes in healthcare policy could 
 negatively impact our business and financial condition;            |

| · | the extent to which global economic and political developments,                                                                         
 including existing regional conflicts, pandemics, natural disasters, and the indirect and/or long-term impact of inflation, will affect 
 our business operations, clinical trials, or financial condition; and                                                                   |

| · | any statement of assumptions underlying any of the foregoing. |

Although forward-looking statements
in this prospectus, including the documents incorporated by reference herein and therein, and in any free writing prospectus that we have
authorized for use in connection with this offering, reflect the good